Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Evofem Biosciences revenue
Evofem Biosciences's revenue is $16.8 million.
What is Evofem Biosciences's revenue?
- Evofem Biosciences's revenue growth from 2020 to 2022 is 3,675.11%.
- Evofem Biosciences has 55 employees, and the revenue per employee ratio is $306,127.
- Evofem Biosciences's peak quarterly revenue was $3.6M in 2024(q1).
- Evofem Biosciences peak revenue was $16.8M in 2022.
- Evofem Biosciences annual revenue for 2021 was 8.2M, 1,748.43% growth from 2020.
- Evofem Biosciences annual revenue for 2022 was 16.8M, 104.23% growth from 2021.
On this page
Zippi applies for you, and finds you a job.
Evofem Biosciences historical revenue
Evofem Biosciences's peak revenue was $16.8M in 2022. The peak quarterly revenue was $3.6M in 2024(q1).
Evofem Biosciences's revenue increased from $446.0k in 2020 to $16.8M currently. That's a 3,675.11% change in annual revenue.
Evofem Biosciences annual revenue
Evofem Biosciences annual revenue over time
| Fiscal year / year | Evofem Biosciences revenue |
|---|---|
| 2020 | $446,000 |
| 2021 | $8.2M |
| 2022 | $16.8M |
Evofem Biosciences jobs nearby
Do you work at Evofem Biosciences?
Did Evofem Biosciences meet its revenue projections?
Evofem Biosciences financial information
| CEO | Saundra L. Pelletier |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 55 |
| Date Founded | 2009 |
| Headquarters | San Diego, California |
| Number of Locations | 1 |
| Revenue | $16.8M |
| Net Income | -$76,698,000 |
| Gross Proft | $12.4M (2022) |
| Tax Rate | -0.0% |
| Total Assets | $25,163,000 |
| Ticker | EVFM |
Evofem Biosciences jobs you might like
Evofem Biosciences financing
Evofem Biosciences received early financing of $25.0M on 2009-12-08.
| Series | Round size | Date |
|---|---|---|
| Series Unknown | $25M | 12/2009 |
| Series C | $20.6M | 12/2012 |
| Series C | $6.7M | 07/2013 |
| Series C | $8M | 02/2014 |
| Post Ipo Equity | $20M | 11/2015 |
| Post Ipo Equity | $25M | 08/2016 |
| Post Ipo Equity | $7.5M | 08/2017 |
| Post Ipo Equity | $30M | 04/2019 |
| Post Ipo Equity | $50M | 06/2019 |
| Post Ipo Equity | $100M | 06/2020 |
| Post Ipo Debt | $25M | 10/2020 |
| Post Ipo Equity | $30M | 03/2021 |
| Post Ipo Equity | $50M | 05/2021 |
Evofem Biosciences investors
| Investors | Security type |
|---|---|
| Numoda Capital Innovations | Series C |
| RUSNANO | Series C |
| AMOREPACIFIC Ventures | Series C |
| Alta Partners | Series C |
| RMI Partners | Series C |
| Domain Associates | Series C |
| Mirae Asset Venture Investment | Series C |
| RUSNANO | Series C |
| AKS Capital | Series C |
| Alta Partners | Series C |
| Domain Associates | Series C |
| Woodford Investment Management | Post Ipo Equity |
| PDL BIOPHARMA, INC. | Post Ipo Equity |
| PDL BIOPHARMA, INC. | Post Ipo Equity |
| Adjuvant | Post Ipo Debt |
Evofem Biosciences competitors
Evofem Biosciences's top competitor, Premier, earned an annual revenue of $1.3B.
Evofem Biosciences's smallest competitor is AcelRx Pharmaceuticals with revenue of $651.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Premier Inc. | $59,611 | $1.3B | 2,600 | 654 |
| AngioDynamics | $50,008 | $303.9M | 1,050 | 10 |
| ReVision Optics | $69,217 | $3.2M | 125 | - |
| Sage Therapeutics | $99,139 | $41.2M | 637 | 1 |
| Cerexa Inc. | $46,963 | $1.3M | 29 | - |
| Aptevo Therapeutics | $46,293 | $3.1M | 58 | - |
| AssuraMed | $53,202 | $76.5M | 750 | - |
| Blueprint Medicines | $84,447 | $508.8M | 495 | 12 |
| Triad Isotopes | $49,154 | $225.0M | 1,000 | - |
| Akebia Therapeutics | $94,635 | $160.2M | 324 | 9 |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of Evofem Biosciences, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Evofem Biosciences. The employee data is based on information from people who have self-reported their past or current employments at Evofem Biosciences. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Evofem Biosciences. The data presented on this page does not represent the view of Evofem Biosciences and its employees or that of Zippia.
Evofem Biosciences may also be known as or be related to EVOFEM BIOSCIENCES, INC., Evofem Biosciences, Evofem Biosciences Inc, Evofem Biosciences, Inc. and Evofem, Inc.